Removal of Toxic Metabolites—Chelation: Manganese Disorders
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.70107 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Hendrik Vogt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, London, UK. Hauptthemen laut MEDLINE: Manganese, Manganese Poisoning, Chelating Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 265 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Manganese (Mn) overload is a characteristic of multiple disease entities, from acquired manganism upon environmental or occupational overexposure, to end‐stage liver disease and certain genetic disorders. The latter include hypermanganesaemia with dystonia 1 and 2 caused by pathogenic variants in the genes encoding the Mn transporters SLC30A10 and SLC39A14. Excess Mn accumulates in the brain, particularly in the globus pallidus, leading to progressive dystonia–parkinsonism. Furthermore, Mn dyshomeostasis is a characteristic feature of common neurodegenerative disorders such as Parkinson's disease, whether as a cause or consequence needs to be determined, suggesting that Mn as an environmental toxicant may play a role in its aetiology. Therefore, there is a need for therapeutics that effectively chelate Mn and remove excess Mn from the brain. This review discusses the Mn chelators currently used in clinical practice, their advantages and disadvantages as well as their adverse effects. Na 2 CaEDTA is the primary chelating agent used to re‐establish Mn homeostasis; however, its burdensome treatment regimen, need for intravenous administration, and lack of metal specificity make it a poor drug for clinical application. The development of novel, Mn‐specific chelating agents is therefore a clinical priority. An ideal chelator would be orally bioavailable, soluble in both lipids and water to reach the sites of metal storage, chemically inert, and non‐toxic whilst retaining chelating abilities at physiological pH. We discuss current progress in identifying novel Mn ligands that have been primarily developed as magnetic resonance imaging contrast agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
- Department of Chemistry, School of Life Sciences, University of Sussex, East Sussex, UK.
- Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, East Sussex, UK.
- Department of Analytical, Environmental and Forensic Sciences, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
ORCID-Profile: Karin Tuschl
Förderung
- Medical Research Council
Zitieren
APA
Vogt, H., Kostakis, G. E., Purchase, R., Spencer, J., & Tuschl, K. (2025). Removal of Toxic Metabolites—Chelation: Manganese Disorders. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70107
Vancouver
Vogt H, Kostakis GE, Purchase R, Spencer J, Tuschl K. Removal of Toxic Metabolites—Chelation: Manganese Disorders. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70107
BibTeX
@article{Vogt2025,
author = {Vogt, Hendrik and Kostakis, George E and Purchase, Rupert and Spencer, John and Tuschl, Karin},
title = {Removal of Toxic Metabolites—Chelation: Manganese Disorders},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.70107}
}
EUVIMED